针对志贺菌和产肠毒素大肠杆菌的人类免疫应答:当前进展与前进路径
本文总结VASE会议中关于志贺菌和产肠毒素大肠杆菌(ETEC)感染与疫苗接种后人类体液和细胞免疫应答的进展,讨论免疫保护相关参数、实验室间检测方法统一及试剂与标准品可及性,并提出促进沟通、统一方法、建立试剂库和扩大探索性研究等具体建议。
要点
- 稳健的免疫学检测方法和明确的保护相关标志物对评估志贺菌和ETEC感染及疫苗免疫应答至关重要。
- 试剂和校准对照品的可及性对标准化检测和实验室间结果可比性具有关键意义。
- 会议提出支持科学家沟通、统一检测方法、建立试剂与校准品库并分发给研究界及扩大探索性研究等建议。
核心结论
- 需要稳健且成熟的免疫学检测方法及可靠的保护相关标志物来充分评估人类对志贺菌和ETEC感染与疫苗接种的免疫应答。
研究设计与样本
- 本文为VASE会议期间举办的「针对志贺菌和ETEC的人类免疫应答:当前进展与前进路径」研讨会的总结,包含四场关于感染和疫苗接种期间志贺菌和ETEC体液与细胞免疫应答当前知识的报告及后续讨论。
主要发现
- 研讨会传播和讨论了志贺菌和ETEC免疫学领域的最新进展,并确定了研究需求。
- 讨论内容涉及临床研究相关的免疫学方法、与保护相关的免疫参数、实验室间检测方法统一以及试剂和标准品的可及性。
关键数值与推荐
- 具体建议包括支持科学家之间的沟通。
- 具体建议包括统一检测方法并共享方案。
- 具体建议包括创建试剂和校准对照品库并将此类材料分发给研究界。
- 具体建议包括扩大探索性研究以更好地理解这些病原体与人类免疫系统之间的相互作用及随之产生的应答。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Robust and well-established immunological assays and firm immune correlates of protection that can predict disease outcome and/or vaccine efficacy are essential to adequately assess human immune responses to infection and vaccination. The availability of reagents and calibrated controls is also critically important to standardize assays and generate comparable results among different laboratories. The workshop "Human Immune Responses against Shigella and ETEC: Current Advances and the Path Forward" held during the VASE meeting provided an opportunity to disseminate and discuss recent advances in the field of Shigella and ETEC immunology, identify research needs, and propose collaborative activities to advance the field. Four presentations featured current knowledge on humoral and cellular immune responses to Shigella and ETEC during infection and vaccination. A discussion followed on immunological methods relevant for clinical studies, immune parameters associated with protection, harmonization of assays among laboratories, and availability of reagents and standards. Specific recommendations proposed to facilitate "the path forward" included supporting communication among scientists, harmonization of assays and sharing of protocols, the creation of a repository of reagents and calibrated controls and distribution of such material to the research community, and expansion of exploratory studies to better understand the interactions between these pathogens and the human immune system and the ensuing responses.
引用
- McArthur MA, Maciel M, Pasetti MF, et al. Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward. Vaccine. 2017. PMID: 28558984. doi:10.1016/j.vaccine.2017.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。